Printer Friendly

ISL FILES IDEs FOR NEARSIGHTEDNESS AND A NOVEL GLAUCOMA TREATMENT

 SAN DIEGO, March 31 /PRNewswire/ -- Intelligent Surgical Lasers Inc. (NASDAQ: ISLS), which designs and manufactures advanced laser systems for the treatment of a broad range of ophthalmic disorders, announced today that it has filed two Investigational Device Exemptions (IDEs) with the U.S. Food and Drug Administration, one for its new Eye Laser System to treat myopia (nearsightedness) and the other for its Model 2001 System to treat glaucoma. This is the first IDE submitted for the Eye Laser System, which was introduced in January 1993, and the fourth IDE for the Model 2001, according to Heinz Gisel, chairman and chief executive officer.
 "The Eye Laser System and the Model 2001 performed well in pre- clinical evaluations for the novel procedures covered in these IDEs, allowing us to achieve two significant milestones in our product development and marketing strategy," Gisel said. "The company hopes to gain FDA approval this summer to commence Phase I clinical trials evaluating the use of its proprietary technology for the correction of refractive disorders and the outpatient treatment of glaucoma."
 The Eye Laser preclinical data demonstrated the concept and feasibility for using the system to treat nearsightedness, as well as farsightedness and astigmatism. This new procedure, called intrastromal ablation, changes the curvature of the eye by "vaporizing" several layers inside the cornea without actually harming the outer layer of the cornea. Because the refractive correction is made within the eye, the procedure avoids traumatizing corneal tissue, thereby shortening patient recovery periods, lessening the pain associated with the procedure and reducing the chances of adverse side effects.
 In the company's continuing strategy to develop therapeutic applications for the Model 2001, ISL has focused part of its research effort on preclinical studies to treat glaucoma, one of the most common eye disorders in people over 40 and the second leading cause of blindness in the United States. This effort has resulted in a novel treatment for glaucoma called internal sclerostomy.
 "In this procedure intraocular pressure is lowered by focusing the laser to create a precise and patent hold from the inside of the eye to the outer layers," Gisel said. "This minute opening allows fluid to flow within the eye, thereby reducing the excessive pressure. Internal sclerostomy may allow the glaucoma surgeon to replace the conventional high-risk operating room surgeries now performed, with an equally effective, lower-risk outpatient procedure. This is preferable, since glaucoma is a disease that must be monitored and controlled throughout the life of the patient.
 "In a time of cost containment, ophthalmic surgeons are looking for highly effective, less invasive alternatives for the correction of visual disorders," Gisel added. "The filing of these IDEs demonstrates that ISL is rapidly making progress in fulfilling these clinical needs."
 Intelligent Surgical Lasers Inc. (ISL) is a development stage biomedical company which designs and manufactures innovative, technologically advanced laser systems for the treatment of a broad range of ophthalmic disorders. Many of these disorders are difficult or impossible to treat with current lasers or traditional medical instruments. Founded in 1987, ISL completed a public offering in September 1992.
 -0- 3/31/93
 /CONTACT: Robert J. Feeney, director of sales and marketing of ISL, 619-552-6700; or Linda Seaton of Keatinge/Seaton Communications, 619-625-2100, for ISL/
 (ISLS)


CO: Intelligent Surgical Lasers Inc. ST: California IN: MTC SU:

JL-KJ -- SD002 -- 1377 03/31/93 09:16 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1993
Words:557
Previous Article:SAN DIEGO-BASED CORPORATION GUARANTEES INVESTMENT TAX CREDIT SAVINGS FOR CUSTOMERS WHETHER PASSED BY CONGRESS, OR NOT
Next Article:WASHINGTON MUTUAL DONATES $10,000 TO AFFORDABLE HOUSING FUND, COMMUNITY REINVESTMENT FUND SAYS
Topics:


Related Articles
PHOENIX LASER SYSTEMS INC. SHIPS SURGICAL LASER WORKSTATION FOR GLAUCOMA TRIALS
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
SUMMIT TECHNOLOGY CLARIFIES EUROPEAN SALES
ISL INTRODUCES NEW LASER SYSTEM FOR REFRACTIVE SURGERY
e/ -- Intelligent Surgical Lasers, Inc. (NASDAQ: ISLS) announced today promising results from clinical studies conducted at the University of...
ISL REPORTS THIRD QUARTER RESULTS
ISL SHIPS TWO EYE LASER SYSTEMS FOR TREATMENT OF MYOPIA AND HYPEROPIA TO ITALY
Donner Corp. International Issues Speculative Buy Recommendation on Coronado Industries, Inc.
FDA Approves LaserSight's LSX for Lasik Treatment of Myopic Astigmatism.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters